Get the Stockscreener App
0.904
0.46%
-0.0042
After Hours:
.89
-0.014
-1.55%
Oncolytics Biotech Inc stock is traded at $0.904, with a volume of 915.16K.
It is down -0.46% in the last 24 hours and up +6.33% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
See More
Previous Close:
$0.9082
Open:
$0.9215
24h Volume:
915.16K
Relative Volume:
0.63
Market Cap:
$107.90M
Revenue:
-
Net Income/Loss:
$-25.91M
P/E Ratio:
-3.5916
EPS:
-0.2517
Net Cash Flow:
$-22.73M
1W Performance:
+14.10%
1M Performance:
+6.33%
6M Performance:
-7.09%
1Y Performance:
-20.00%
1-Day Range:
$0.885
$0.94
1-Week Range:
$0.80
$1.08
52-Week Range:
$0.77
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Name
Oncolytics Biotech Inc
Sector
Industry
Phone
(403) 670-7377
Address
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.904 | 110.87M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
477.08 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.45 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.93 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.44 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.14 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com India
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com
Cancer trial using pelareorep seeks FDA input on path to possible approval - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1%What's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc. Replaces Ernst & Young with Baker Tilly as Independent Auditor in 2026 Corporate Restructuring – Minichart - Minichart
Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor - Stock Titan
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Price to sales forward of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech | 8-K: Current report - Moomoo
Oncolytics Biotech StockWeekly review and sector backdrop - AD HOC NEWS
Oncolytics Biotech | F-10POS: Others - Moomoo
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oncolytics Biotech Secures New Pelareorep Manufacturing Patent - The Globe and Mail
Oncolytics (ONCY) Secures New Patent for Pelareorep Manufacturin - GuruFocus
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Yahoo Finance
Oncolytics receives U.S. patent for pelareorep manufacturing By Investing.com - Investing.com South Africa
Oncolytics Gets US Patent for Pelareorep Manufacturing Process - marketscreener.com
Oncolytics receives U.S. patent for pelareorep manufacturing - Investing.com
Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process - TradingView
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 - The Manila Times
New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044 - Stock Titan
Oncolytics Builds a 20-Year Patent Fortress for Its Cancer Immunotherapy - BriefGlance
Oncolytics Biotech® to Participate in a Panel Presentation at Ca - GuruFocus
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating - Moomoo
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights - ACCESS Newswire
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
Oncolytics Biotech (ONCY) Jefferies Global Healthcare Conference 2026 Summary - Quartr
ONCY: Pivotal data for a novel IV oncolytic virus in GI cancers expected by year-end - TradingView
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oncolytics Biotech Inc Stock (ONCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.27%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):